

# Rino Rappuoli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6619548/rino-rappuoli-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

611 papers	51,234 citations	117 h-index	198 g-index
659 ext. papers	57,104 ext. citations	9.6 avg, IF	7.58 L-index

#	Paper	IF	Citations
611	Innovative vaccine approaches-a Keystone Symposia report.. <i>Annals of the New York Academy of Sciences</i> , <b>2022</b> ,	6.5	1
610	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.. <i>Pharmacological Reviews</i> , <b>2022</b> , 74, 313-339	22.5	0
609	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules.. <i>Nature Immunology</i> , <b>2022</b> ,	19.1	14
608	The trillion dollar vaccine gap.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabn4342	17.5	1
607	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection.. <i>Nature Communications</i> , <b>2022</b> , 13, 2263	17.4	0
606	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119, e2120976119 <sup>11.5</sup>	11.5	2
605	Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. <i>Pediatric Infectious Disease Journal</i> , <b>2021</b> , 40, e66-e71	3.4	1
604	Recent advances in the prevention of meningococcal B disease: Real evidence from 4CMenB vaccination. <i>Vacunas (English Edition)</i> , <b>2021</b> , 22, 189-202	0.2	
603	Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among <i>S. flexneri</i> serotypes. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009826	4.8	2
602	Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. <i>Nature</i> , <b>2021</b> ,	50.4	22
601	Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. <i>Npj Vaccines</i> , <b>2021</b> , 6, 130	9.5	1
600	Immunodominant antibody germplines in COVID-19. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	14
599	Bacteriophages, a multi-tool to fight infectious disease.. <i>Med</i> , <b>2021</b> , 2, 209-210	31.7	1
598	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , <b>2021</b> , 594, 253-258	50.4	92
597	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , <b>2021</b> , 184, 1821-1835.e16	56.2	90
596	The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e14035	12	3
595	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , <b>2021</b> , 27, 759-761	50.5	39

594	Antibodies Elicited by the GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 671325	8.4	9
593	4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 307-316	6.2	8
592	Antibodies, epicenter of SARS-CoV-2 immunology. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 821-824	12.7	6
591	Vaccinology in the post-COVID-19 era. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	30
590	The role of vaccines in combatting antimicrobial resistance. <i>Nature Reviews Microbiology</i> , <b>2021</b> , 19, 287-302	10.2	58
589	Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. <i>Journal of Infection</i> , <b>2021</b> , 83, 17-26	18.9	4
588	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	106
587	Efficacy, safety, and immunogenicity of the 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. <i>EClinicalMedicine</i> , <b>2021</b> , 39, 101076	11.3	10
586	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16	56.2	34
585	Vaccines 2020: The era of the digital vaccine is here.. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabm3249	17.5	2
584	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. <i>Vaccine</i> , <b>2020</b> , 38, 7542-7550	4.1	10
583	Structure of a protective epitope reveals the importance of acetylation of serogroup A capsular polysaccharide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 29795-29802	11.5	12
582	Vaccines Against Antimicrobial Resistance. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1048	8.4	34
581	4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008882	7.6	3
580	Development of vaccines at the time of COVID-19. <i>MicroLife</i> , <b>2020</b> , 1, uqaa003	5	1
579	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma <b>2020</b> ,		153
578	Vaccine innovations for emerging infectious diseases-a symposium report. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1462, 14-26	6.5	10
577	Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia. <i>Trends in Microbiology</i> , <b>2020</b> , 28, 315-326	12.4	9

576	Timeline: Vaccines. <i>Cell</i> , <b>2020</b> , 183, 552	56.2	2
575	Vaccines against Meningococcal Diseases. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	31
574	Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. <i>Nature Communications</i> , <b>2020</b> , 11, 4994	17.4	0
573	Rational Design of a Glycoconjugate Vaccine against Group A. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
572	Vaccines as remedy for antimicrobial resistance and emerging infections. <i>Current Opinion in Immunology</i> , <b>2020</b> , 65, 102-106	7.8	4
571	Transforming vaccine development. <i>Seminars in Immunology</i> , <b>2020</b> , 50, 101413	10.7	15
570	Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM conjugate vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 24443-24449	11.5	12
569	Meningococcal factor H binding protein as immune evasion factor and vaccine antigen. <i>FEBS Letters</i> , <b>2020</b> , 594, 2657-2669	3.8	6
568	Long noncoding RNAs are involved in multiple immunological pathways in response to vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 17121-17126	11.5	28
567	Human monoclonal antibodies for discovery, therapy, and vaccine acceleration. <i>Current Opinion in Immunology</i> , <b>2019</b> , 59, 130-134	7.8	8
566	Inhibiting neuraminidase can make the difference. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 251-252	16.6	0
565	Genetic Meningococcal Antigen Typing System (gMATs): A genotyping tool that predicts 4CMenB strain coverage worldwide. <i>Vaccine</i> , <b>2019</b> , 37, 991-1000	4.1	43
564	Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 113	8.4	53
563	Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction. <i>Trends in Parasitology</i> , <b>2019</b> , 35, 483-486	6.4	16
562	Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. <i>Vaccine</i> , <b>2019</b> , 37, 3006-3021	4.1	46
561	Self-Assembling Nanoparticles Usher in a New Era of Vaccine Design. <i>Cell</i> , <b>2019</b> , 176, 1245-1247	56.2	13
560	Profiling Vaccines for an Immunosenescent and Multimorbid Population. <i>Practical Issues in Geriatrics</i> , <b>2019</b> , 37-41	0.1	
559	Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. <i>Expert Review of Vaccines</i> , <b>2019</b> , 18, 309-322	5.2	10

558	Vaccine Evolution and Its Application to Fight Modern Threats. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1722	8.4	19
557	Vaccines and global health: In search of a sustainable model for vaccine development and delivery. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	67
556	On the mechanisms of conjugate vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 14-16	11.5	57
555	Vaccines: An achievement of civilization, a human right, our health insurance for the future. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 7-9	16.6	15
554	Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. <i>Scientific Reports</i> , <b>2018</b> , 8, 3700	4.9	32
553	Short-term and mid-term solutions for influenza vaccines. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, 832-835	8.3	1
552	Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1068	8.4	111
551	Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines. <i>Molecules</i> , <b>2018</b> , 23,	4.8	32
550	Farewell Stan Stanley Falkow: 1934-2018. <i>Environmental Microbiology</i> , <b>2018</b> , 20, 2322-2333	5.2	
549	Meningococcal B vaccine (4CMenB): the journey from research to real world experience. <i>Expert Review of Vaccines</i> , <b>2018</b> , 17, 1111-1121	5.2	37
548	Technologies to address antimicrobial resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 12887-12895	11.5	94
547	Antimicrobial resistance and the role of vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 12868-12871	11.5	69
546	Vision for a systems architecture to integrate and transform population health. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 12595-12602	11.5	5
545	Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 10428-10433	11.5	55
544	Glycoconjugate vaccines: Principles and mechanisms. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	92
543	Sustainable vaccine development: a vaccine manufacturer's perspective. <i>Current Opinion in Immunology</i> , <b>2018</b> , 53, 111-118	7.8	13
542	Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. <i>Seminars in Immunology</i> , <b>2018</b> , 39, 14-21	10.7	277
541	Efficacy, immunogenicity, and safety of a parenteral vaccine against <i>Helicobacter pylori</i> in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 698-707	18.8	33

540	Core values for vaccine evaluation. <i>Vaccine</i> , <b>2017</b> , 35 Suppl 1, A57-A62	4.1	6
539	Emerging infectious diseases: A proactive approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 4055-4059	11.5	96
538	Structure of a protective epitope of group B type III capsular polysaccharide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 5017-5022	11.5	45
537	An unwanted guest: <i>Neisseria meningitidis</i> - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence. <i>Expert Review of Anti-Infective Therapy</i> , <b>2017</b> , 15, 689-701	5.5	8
536	Emerging experience with meningococcal serogroup B protein vaccines. <i>Expert Review of Vaccines</i> , <b>2017</b> , 16, 433-451	5.2	44
535	Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. <i>Vaccine</i> , <b>2017</b> , 35 Suppl 1, A46-A49	4.1	11
534	Improving accountability in vaccine decision-making. <i>Expert Review of Vaccines</i> , <b>2017</b> , 16, 1057-1066	5.2	7
533	2. How is the economic assessment of vaccines performed today?. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1335163	3.7	7
532	Compare voting systems to improve them. <i>Nature</i> , <b>2017</b> , 541, 151-153	50.4	7
531	Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1335162	3.7	8
530	3. How comprehensive can we be in the economic assessment of vaccines?. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1336044	3.7	5
529	Deploy vaccines to fight superbugs. <i>Nature</i> , <b>2017</b> , 552, 165-167	50.4	81
528	Vaccines for <i>Staphylococcus aureus</i> and Target Populations. <i>Current Topics in Microbiology and Immunology</i> , <b>2017</b> , 409, 491-528	3.3	25
527	Multicriteria decision analysis and core values for enhancing vaccine-related decision-making. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 345ps14	17.5	10
526	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 1853-8	11.5	111
525	Self-assembling protein nanoparticles in the design of vaccines. <i>Computational and Structural Biotechnology Journal</i> , <b>2016</b> , 14, 58-68	6.8	189
524	<i>Staphylococcus aureus</i> coagulase R domain, a new evasion mechanism and vaccine target. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 292	16.6	3
523	The role of structural proteomics in vaccine development: recent advances and future prospects. <i>Expert Review of Proteomics</i> , <b>2016</b> , 13, 55-68	4.2	21

522	One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147767	3.7	39
521	Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin. <i>Vaccine Journal</i> , <b>2016</b> , 23, 442-50		10
520	Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 2714-9	11.5	60
519	Strategic Planning in Population Health and Public Health Practice: A Call to Action for Higher Education. <i>Milbank Quarterly</i> , <b>2016</b> , 94, 109-25	3.9	8
518	Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. <i>Scientific Reports</i> , <b>2016</b> , 6, 29063	4.9	29
517	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 469-81	16.6	210
516	Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 294ra105	17.5	167
515	Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines. <i>Vaccine</i> , <b>2015</b> , 33, 3628-35	4.1	18
514	Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 6431-6	11.5	63
513	Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 3680-5	11.5	125
512	Developing vaccines for an aging population. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 281ps8	17.5	17
511	Lessons from Reverse Vaccinology for viral vaccine design. <i>Current Opinion in Virology</i> , <b>2015</b> , 11, 89-97	7.5	22
510	Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination. <i>Journal of Immunology</i> , <b>2015</b> , 195, 1617-27	5.3	53
509	The Human Pathogen Streptococcus pyogenes Releases Lipoproteins as Lipoprotein-rich Membrane Vesicles. <i>Molecular and Cellular Proteomics</i> , <b>2015</b> , 14, 2138-49	7.6	33
508	Neisseria meningitidis: pathogenesis and immunity. <i>Current Opinion in Microbiology</i> , <b>2015</b> , 23, 68-72	7.9	88
507	LytM proteins play a crucial role in cell separation, outer membrane composition, and pathogenesis in nontypeable Haemophilus influenzae. <i>MBio</i> , <b>2015</b> , 6, e02575	7.8	23
506	Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response to Staphylococcus aureus. <i>FEMS Microbiology Reviews</i> , <b>2015</b> , 39, 750-63	15.1	28
505	Ebola vaccine R&D: Filling the knowledge gaps. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 317ps24	17.5	37



504	Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk. <i>MBio</i> , <b>2015</b> , 6, e01765-15	7.8	70
503	Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 1767-72	11.5	105
502	Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120807	3.7	25
501	Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. <i>Journal of Virology</i> , <b>2014</b> , 88, 5502-10	6.6	45
500	Cost effectiveness has its place, but so does common sense. <i>BMJ, The</i> , <b>2014</b> , 349, g6759	5.9	3
499	Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 5439-44	11.5	81
498	Inner Workings: 1885, the first rabies vaccination in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 12273	11.5	18
497	Changing route: aerosol vaccine against tuberculosis. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 901-2	25.5	6
496	Vaccines: science, health, longevity, and wealth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 12282	11.5	15
495	Vaccines for the 21st century. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 708-20	12	241
494	From empiricism to rational design: a personal perspective of the evolution of vaccine development. <i>Nature Reviews Immunology</i> , <b>2014</b> , 14, 505-14	36.5	138
493	Role of ARF6, Rab11 and external Hsp90 in the trafficking and recycling of recombinant-soluble Neisseria meningitidis adhesin A (rNadA) in human epithelial cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e110047	3.7	12
492	Neisseria adhesin A variation and revised nomenclature scheme. <i>Vaccine Journal</i> , <b>2014</b> , 21, 966-71		46
491	Bringing influenza vaccines into the 21st century. <i>Human Vaccines and Immunotherapeutics</i> , <b>2014</b> , 10, 600-4	4.4	13
490	Designing vaccines for the twenty-first century society. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 12	8.4	69
489	HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN $\alpha$ and Ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 458-65	3.4	15
488	Vaccines, new opportunities for a new society. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 12288-93	11.5	171
487	Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 17128-33	11.5	56



486	Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 427-32	11.5	51
485	A priority-setting aid for new vaccine candidates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 3199-200	11.5	12
484	Vaccine adjuvants: the future is bright. Interview by Jenaid Rees. <i>Expert Review of Vaccines</i> , <b>2013</b> , 12, 727-9	5.2	3
483	Correlates of protection against influenza infection in humans--on the path to a universal vaccine?. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 470-6	7.8	33
482	Auto ADP-ribosylation of NarE, a Neisseria meningitidis ADP-ribosyltransferase, regulates its catalytic activities. <i>FASEB Journal</i> , <b>2013</b> , 27, 4723-30	0.9	7
481	Finding epitopes with computers. <i>Chemistry and Biology</i> , <b>2013</b> , 20, 1205-6		4
480	Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 14330-5	11.5	81
479	The history of MF59( ) adjuvant: a phoenix that arose from the ashes. <i>Expert Review of Vaccines</i> , <b>2013</b> , 12, 13-30	5.2	190
478	Protective efficacy induced by recombinant Clostridium difficile toxin fragments. <i>Infection and Immunity</i> , <b>2013</b> , 81, 2851-60	3.7	33
477	Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 19077-82	11.5	47
476	Perspectives on vaccine development for the elderly. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 529-34	7.8	7
475	Immunisation against meningococcus B. <i>Lancet, The</i> , <b>2013</b> , 382, 935-6	40	1
474	Reverse vaccinology in the 21st century: improvements over the original design. <i>Annals of the New York Academy of Sciences</i> , <b>2013</b> , 1285, 115-32	6.5	59
473	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 416-25	25.5	233
472	Synthetic generation of influenza vaccine viruses for rapid response to pandemics. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 185ra68	17.5	134
471	Aflunov : a vaccine tailored for pre-pandemic and pandemic approaches against influenza. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 121-35	5.4	9
470	Conservation of meningococcal antigens in the genus Neisseria. <i>MBio</i> , <b>2013</b> , 4, e00163-13	7.8	44
469	Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 3304-9	11.5	109

468	The gracefully aging immune system. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 185ps8	17.5	90
467	Preventing newborn infection with maternal immunization. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 195ps11	1.5	9
466	Optimized fluorescent labeling to identify memory B cells specific for <i>Neisseria meningitidis</i> serogroup B vaccine antigens ex vivo. <i>Immunity, Inflammation and Disease</i> , <b>2013</b> , 1, 3-13	2.4	5
465	The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 21095-100	11.5	97
464	Rapidly produced SAM( ) vaccine against H7N9 influenza is immunogenic in mice. <i>Emerging Microbes and Infections</i> , <b>2013</b> , 2, e52	18.9	143
463	Vaccines, reverse vaccinology, and bacterial pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2013</b> , 3, a012476	5.4	87
462	<i>Helicobacter pylori</i> CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 328	8.4	49
461	An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. <i>PLoS ONE</i> , <b>2013</b> , 8, e65043	3.7	42
460	Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , <b>2012</b> , 120, 750-60	3.4	28
459	Human heat shock protein (Hsp) 90 interferes with <i>Neisseria meningitidis</i> adhesin A (NadA)-mediated adhesion and invasion. <i>Cellular Microbiology</i> , <b>2012</b> , 14, 368-85	3.9	26
458	Structural vaccinology starts to deliver. <i>Nature Reviews Microbiology</i> , <b>2012</b> , 10, 807-13	22.2	99
457	Vaccines and antibiotic resistance. <i>Current Opinion in Microbiology</i> , <b>2012</b> , 15, 596-602	7.9	68
456	The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. <i>Vaccine</i> , <b>2012</b> , 30 Suppl 2, B87-97	4.1	248
455	Nonviral delivery of self-amplifying RNA vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 14604-9	11.5	376
454	Improving influenza vaccines. <i>Expert Review of Vaccines</i> , <b>2012</b> , 11, 871-2	5.2	3
453	Recombinant bacterial vaccines. <i>Current Opinion in Immunology</i> , <b>2012</b> , 24, 337-42	7.8	21
452	Development of an influenza virus protein array using Sortagging technology. <i>Bioconjugate Chemistry</i> , <b>2012</b> , 23, 1119-26	6.3	18
451	The factor H binding protein of <i>Neisseria meningitidis</i> interacts with xenosiderophores in vitro. <i>Biochemistry</i> , <b>2012</b> , 51, 9384-93	3.2	16

450	Influenza: options to improve pandemic preparation. <i>Science</i> , <b>2012</b> , 336, 1531-3	33.3	57
449	Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. <i>Vaccine Journal</i> , <b>2012</b> , 19, 1609-17		54
448	RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. <i>Infection and Immunity</i> , <b>2012</b> , 80, 451-60	3.7	36
447	Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 5229-34	11.5	97
446	Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. <i>Vaccine Journal</i> , <b>2012</b> , 19, 991-8		12
445	ADITEC: joining forces for next-generation vaccines. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 128cm4	17.5	17
444	Toward a meningitis-free world. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 123ps5	17.5	18
443	Human papillomavirus E2 protein: a potential key regulator of viral cell pathogenesis. <i>Pathogens and Global Health</i> , <b>2012</b> , 106, 141	3.1	
442	HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. <i>PLoS ONE</i> , <b>2012</b> , 7, e48781	3.7	40
441	MF59 adjuvant: the best insurance against influenza strain diversity. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 447-62	5.2	109
440	The design of semi-synthetic and synthetic glycoconjugate vaccines. <i>Expert Opinion on Drug Discovery</i> , <b>2011</b> , 6, 1045-66	6.2	144
439	Systems vaccinomics: the road ahead for vaccinology. <i>OMICS A Journal of Integrative Biology</i> , <b>2011</b> , 15, 529-31	3.8	29
438	Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. <i>Vaccine</i> , <b>2011</b> , 29, 712-20	4.1	61
437	Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. <i>Vaccine</i> , <b>2011</b> , 29, 1072-81	4.1	44
436	Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. <i>Vaccine</i> , <b>2011</b> , 29, 4739-44	4.1	90
435	Vaccine discovery and translation of new vaccine technology. <i>Lancet, The</i> , <b>2011</b> , 378, 360-8	40	68
434	Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. <i>Pediatric Infectious Disease Journal</i> , <b>2011</b> , 30, 1081-5	3.4	244
433	Influenza vaccine immunology. <i>Immunological Reviews</i> , <b>2011</b> , 239, 167-77	11.3	125

432	A 2020 vision for vaccines against HIV, tuberculosis and malaria. <i>Nature</i> , <b>2011</b> , 473, 463-9	50.4	206
431	Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. <i>Biologicals</i> , <b>2011</b> , 39, 195-204	1.8	81
430	Designing the next generation of vaccines for global public health. <i>OMICS A Journal of Integrative Biology</i> , <b>2011</b> , 15, 545-66	3.8	51
429	Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. <i>Journal of Immunology</i> , <b>2011</b> , 186, 5896-906	5.3	84
428	A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44. <i>FASEB Journal</i> , <b>2011</b> , 25, 3622-33	0.9	37
427	Rational design of a meningococcal antigen inducing broad protective immunity. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 91ra62	17.5	118
426	Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. <i>Journal of Virology</i> , <b>2011</b> , 85, 2851-8	6.6	36
425	MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 85ra48	17.5	260
424	Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. <i>Journal of Molecular Cell Biology</i> , <b>2011</b> , 3, 144-6	6.3	4
423	Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 4494-9	11.5	170
422	Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 9238-43	11.5	146
421	Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 11169-74	11.5	127
420	Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 9619-24	11.5	193
419	Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 10278-83	11.5	107
418	Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002027	7.6	111
417	Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. <i>Infection and Immunity</i> , <b>2011</b> , 79, 970-81	3.7	61
416	Jean-Marc Reyrat (29/04/1967-28/10/2009). <i>Molecular Microbiology</i> , <b>2010</b> , 75, 1059-1060	4.1	78
415	Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. <i>Nature Reviews Microbiology</i> , <b>2010</b> , 8, 393-9	22.2	91

414	Supramolecular organization of the repetitive backbone unit of the <i>Streptococcus pneumoniae</i> pilus. <i>PLoS ONE</i> , <b>2010</b> , 5, e10919	3.7	46
413	A crisis of public confidence in vaccines. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 61mr1	17.5	94
412	Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 15ra5	17.5	204
411	<i>Neisseria meningitidis</i> GNA2132, a heparin-binding protein that induces protective immunity in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 3770-5	11.5	172
410	H1N1: can a pandemic cycle be broken?. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 24ps14	17.5	6
409	Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic <i>Escherichia coli</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 9072-7	11.5	197
408	Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 19490-5	11.5	239
407	Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. <i>Vaccine</i> , <b>2010</b> , 28, 2416-27	4.1	29
406	Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. <i>Vaccine</i> , <b>2010</b> , 28, 5023-30	4.1	70
405	Evaluation of a Group A <i>Streptococcus</i> synthetic oligosaccharide as vaccine candidate. <i>Vaccine</i> , <b>2010</b> , 29, 104-14	4.1	55
404	Towards a vaccine against <i>Escherichia coli</i> -associated urinary tract infections. <i>Future Microbiology</i> , <b>2010</b> , 5, 351-4	2.9	5
403	GTR contributes to the systemic adjuvant activity of the <i>Escherichia coli</i> heat-labile enterotoxin. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 754-63	6.1	3
402	New adjuvants for human vaccines. <i>Current Opinion in Immunology</i> , <b>2010</b> , 22, 411-6	7.8	304
401	Reverse vaccinology: developing vaccines in the era of genomics. <i>Immunity</i> , <b>2010</b> , 33, 530-41	32.3	329
400	Identification of an iron-sulfur cluster that modulates the enzymatic activity in NarE, a <i>Neisseria meningitidis</i> ADP-ribosyltransferase. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 33040-7	5.4	10
399	Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro. <i>Vaccine Journal</i> , <b>2009</b> , 16, 1693-5		4
398	Public health. Rethinking influenza. <i>Science</i> , <b>2009</b> , 326, 50	33.3	17
397	Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. <i>Infection and Immunity</i> , <b>2009</b> , 77, 292-9	3.7	93

396	SR-A, MARCO and TLRs differentially recognise selected surface proteins from <i>Neisseria meningitidis</i> : an example of fine specificity in microbial ligand recognition by innate immune receptors. <i>Journal of Innate Immunity</i> , <b>2009</b> , 1, 153-63	6.9	34
395	The key role of genomics in modern vaccine and drug design for emerging infectious diseases. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000612	6	93
394	Seasonal influenza vaccine provides priming for A/H1N1 immunization. <i>Science Translational Medicine</i> , <b>2009</b> , 1, 12re1	17.5	41
393	Solution structure of the factor H-binding protein, a survival factor and protective antigen of <i>Neisseria meningitidis</i> . <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 9022-6	5.4	52
392	Sortase A confers protection against <i>Streptococcus pneumoniae</i> in mice. <i>Infection and Immunity</i> , <b>2009</b> , 77, 2957-61	3.7	20
391	Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. <i>Journal of Immunology</i> , <b>2009</b> , 183, 1892-9	5.3	49
390	Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 3877-82	11.5	215
389	The use of genomics in microbial vaccine development. <i>Drug Discovery Today</i> , <b>2009</b> , 14, 252-60	8.8	102
388	Involvement of the intrinsic and extrinsic cell-death pathways in the induction of apoptosis of mature lymphocytes by the <i>Escherichia coli</i> heat-labile enterotoxin. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 439-46	6.1	12
387	Generating memory with vaccination. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 2100-5	6.1	39
386	Molecular architecture of <i>Streptococcus pneumoniae</i> TIGR4 pili. <i>EMBO Journal</i> , <b>2009</b> , 28, 3921-30	13	88
385	HadA is an atypical new multifunctional trimeric coiled-coil adhesin of <i>Haemophilus influenzae</i> biogroup <i>aegyptius</i> , which promotes entry into host cells. <i>Cellular Microbiology</i> , <b>2009</b> , 11, 1044-63	3.9	33
384	Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. <i>Vaccine</i> , <b>2009</b> , 27, 1579-84	4.1	46
383	Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. <i>Vaccine</i> , <b>2009</b> , 27, 2794-803	4.1	106
382	Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of <i>Neisseria meningitidis</i> . <i>Journal of Molecular Biology</i> , <b>2009</b> , 386, 97-108	6.5	41
381	Vaccinology in the genome era. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 2515-25	15.9	115
380	Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of <i>Escherichia coli</i> heat labile toxin. <i>PLoS ONE</i> , <b>2009</b> , 4, e6999	3.7	211
379	Development of vaccines against <i>Helicobacter pylori</i> . <i>Expert Review of Vaccines</i> , <b>2009</b> , 8, 1037-49	5.2	69



378	Toll-free immunity?. <i>Nature Medicine</i> , <b>2008</b> , 14, 1318-9	50.5	6
377	Microbiology in the post-genomic era. <i>Nature Reviews Microbiology</i> , <b>2008</b> , 6, 419-30	22.2	281
376	Structure-based antigen design: a strategy for next generation vaccines. <i>Trends in Biotechnology</i> , <b>2008</b> , 26, 659-67	15.1	126
375	A second pilus type in <i>Streptococcus pneumoniae</i> is prevalent in emerging serotypes and mediates adhesion to host cells. <i>Journal of Bacteriology</i> , <b>2008</b> , 190, 5480-92	3.5	143
374	Vaccine adjuvants: the dream becomes real. <i>Hum Vaccin</i> , <b>2008</b> , 4, 347-9		58
373	Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A. <i>PLoS Pathogens</i> , <b>2008</b> , 4, e1000026	7.6	104
372	Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. <i>Infection and Immunity</i> , <b>2008</b> , 76, 1766-73	3.7	14
371	Genome-based vaccine development: a short cut for the future. <i>Hum Vaccin</i> , <b>2008</b> , 4, 184-8		30
370	Molecular and cellular signatures of human vaccine adjuvants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 10501-6	11.5	362
369	Pilus operon evolution in <i>Streptococcus pneumoniae</i> is driven by positive selection and recombination. <i>PLoS ONE</i> , <b>2008</b> , 3, e3660	3.7	19
368	Alum adjuvant activity: unraveling a century old mystery. <i>European Journal of Immunology</i> , <b>2008</b> , 38, 2068-71	16.1	164
367	Bridging the knowledge gaps in vaccine design. <i>Nature Biotechnology</i> , <b>2007</b> , 25, 1361-6	44.5	143
366	Identification of a new OmpA-like protein in <i>Neisseria gonorrhoeae</i> involved in the binding to human epithelial cells and in vivo colonization. <i>Molecular Microbiology</i> , <b>2007</b> , 64, 1391-403	4.1	33
365	RrgA is a pilus-associated adhesin in <i>Streptococcus pneumoniae</i> . <i>Molecular Microbiology</i> , <b>2007</b> , 66, 329-40	4.1	134
364	The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 429-39	8.8	88
363	Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 5115-20	11.5	441
362	Clonal success of piliated penicillin nonsusceptible pneumococci. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12907-12	11.5	73
361	The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. <i>Journal of Immunology</i> , <b>2007</b> , 179, 5346-57	5.3	27



360	Invariant NKT cells sustain specific B cell responses and memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 3984-9	11.5	198
359	<i>Streptococcus pneumoniae</i> pilus subunits protect mice against lethal challenge. <i>Infection and Immunity</i> , <b>2007</b> , 75, 1059-62	3.7	117
358	Expression and selective up-regulation of toxin-related mono ADP-ribosyltransferases by pathogen-associated molecular patterns in alveolar epithelial cells. <i>FEBS Letters</i> , <b>2007</b> , 581, 4199-204	3.8	9
357	Solution structure of the immunodominant domain of protective antigen GNA1870 of <i>Neisseria meningitidis</i> . <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 7220-7	5.4	36
356	Identification of a 35-Kilodalton <i>Mycobacterium tuberculosis</i> Protein Containing B- and T-Cell Epitopes. <i>Infection and Immunity</i> , <b>2006</b> , 74, 2504-2504	3.7	78
355	A universal vaccine for serogroup B meningococcus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 10834-9	11.5	588
354	In vivo dissection of the <i>Helicobacter pylori</i> Fur regulatory circuit by genome-wide location analysis. <i>Journal of Bacteriology</i> , <b>2006</b> , 188, 4654-62	3.5	78
353	Effect of <i>Neisseria meningitidis</i> fur mutations on global control of gene transcription. <i>Journal of Bacteriology</i> , <b>2006</b> , 188, 2483-92	3.5	55
352	A pneumococcal pilus influences virulence and host inflammatory responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 2857-62	11.5	369
351	Mucosal administration of Ag85B-ESAT-6 protects against infection with <i>Mycobacterium tuberculosis</i> and boosts prior bacillus Calmette-Guerin immunity. <i>Journal of Immunology</i> , <b>2006</b> , 177, 6353-60	5.3	153
350	Identification of <i>Neisseria meningitidis</i> nonlipopolysaccharide ligands for class A macrophage scavenger receptor by using a novel assay. <i>Infection and Immunity</i> , <b>2006</b> , 74, 5191-9	3.7	47
349	Group B <i>Streptococcus</i> crosses human epithelial cells by a paracellular route. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 241-50	7	43
348	Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. <i>Vaccine Journal</i> , <b>2006</b> , 13, 1010-3		63
347	Mechanisms of pathogenesis and prevention of meningococcal disease. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2006</b> , 3, 273-279		
346	Meningococcal diseases: From genomes to vaccines. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2006</b> , 3, 129-136		1
345	Post-genomic vaccine development. <i>FEBS Letters</i> , <b>2006</b> , 580, 2985-92	3.8	94
344	Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. <i>Current Opinion in Microbiology</i> , <b>2006</b> , 9, 532-6	7.9	63
343	Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. <i>Vaccine</i> , <b>2006</b> , 24, 2161-8	4.1	42

342	Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. <i>Vaccine</i> , <b>2006</b> , 24, 5093-107	4.1	142
341	Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. <i>Molecular Microbiology</i> , <b>2006</b> , 61, 631-44	4.1	77
340	Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. <i>Scandinavian Journal of Immunology</i> , <b>2006</b> , 63, 223-31	3.4	29
339	Vaccine manufacturing: challenges and solutions. <i>Nature Biotechnology</i> , <b>2006</b> , 24, 1377-83	44.5	235
338	Pili in gram-positive pathogens. <i>Nature Reviews Microbiology</i> , <b>2006</b> , 4, 509-19	22.2	354
337	Group B Streptococcus: global incidence and vaccine development. <i>Nature Reviews Microbiology</i> , <b>2006</b> , 4, 932-42	22.2	239
336	Novel approaches to pediatric vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , <b>2006</b> , 58, 29-51	18.5	31
335	A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. <i>Hum Vaccin</i> , <b>2005</b> , 1, 85-90		19
334	Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 13950-5	11.5	1585
333	Identification of a universal Group B streptococcus vaccine by multiple genome screen. <i>Science</i> , <b>2005</b> , 309, 148-50	33.3	446
332	The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 81-8	7	27
331	The microbial pan-genome. <i>Current Opinion in Genetics and Development</i> , <b>2005</b> , 15, 589-94	4.9	856
330	Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. <i>Advances in Experimental Medicine and Biology</i> , <b>2005</b> , 568, 217-23	3.6	31
329	Application of microbial genomic science to advanced therapeutics. <i>Annual Review of Medicine</i> , <b>2005</b> , 56, 459-74	17.4	32
328	Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. <i>Journal of Drug Targeting</i> , <b>2005</b> , 13, 489-98	5.4	45
327	Neisseria meningitidis NadA is a new invasins which promotes bacterial adhesion to and penetration into human epithelial cells. <i>Molecular Microbiology</i> , <b>2005</b> , 55, 687-98	4.1	191
326	Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. <i>Microbes and Infection</i> , <b>2005</b> , 7, 1386-91	9.3	13
325	The response of primary articular chondrocytes to micrometric surface topography and sulphated hyaluronic acid-based matrices. <i>Cell Biology International</i> , <b>2005</b> , 29, 605-15	4.5	28

324	Vaccinology at the beginning of the 21st century. <i>Current Opinion in Immunology</i> , <b>2005</b> , 17, 411-8	7.8	68
323	Ng-MIP, a surface-exposed lipoprotein of <i>Neisseria gonorrhoeae</i> , has a peptidyl-prolyl cis/trans isomerase (PPIase) activity and is involved in persistence in macrophages. <i>Molecular Microbiology</i> , <b>2005</b> , 58, 669-81	4.1	91
322	Opinion: Cell entry machines: a common theme in nature?. <i>Nature Reviews Microbiology</i> , <b>2005</b> , 3, 349-58	22.2	26
321	The impact of genomics on vaccine design. <i>Trends in Biotechnology</i> , <b>2005</b> , 23, 84-91	15.1	69
320	The <i>Escherichia coli</i> heat-labile enterotoxin induces apoptosis of immature lymphocytes in vivo via a glucocorticoid-dependent pathway. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 3505-15	6.1	8
319	SARS vaccine protective in mice. <i>Emerging Infectious Diseases</i> , <b>2005</b> , 11, 1312-4	10.2	36
318	SARS: understanding the virus and development of rational therapy. <i>Current Molecular Medicine</i> , <b>2005</b> , 5, 677-97	2.5	16
317	Genome analysis reveals pili in Group B <i>Streptococcus</i> . <i>Science</i> , <b>2005</b> , 309, 105	33.3	255
316	In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in <i>Helicobacter pylori</i> . <i>Journal of Bacteriology</i> , <b>2005</b> , 187, 7703-15	3.5	82
315	CrgA is an inducible LysR-type regulator of <i>Neisseria meningitidis</i> , acting both as a repressor and as an activator of gene transcription. <i>Journal of Bacteriology</i> , <b>2005</b> , 187, 3421-30	3.5	47
314	Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. <i>Journal of Virology</i> , <b>2005</b> , 79, 13915-23	6.6	38
313	Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. <i>Infection and Immunity</i> , <b>2005</b> , 73, 5835-41	3.7	23
312	A novel glyco-conjugate vaccine against fungal pathogens. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 597-606	16.6	356
311	Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the <i>Neisseria meningitidis</i> serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. <i>Infection and Immunity</i> , <b>2005</b> , 73, 8256-65	3.7	52
310	The region comprising amino acids 100 to 255 of <i>Neisseria meningitidis</i> lipoprotein GNA 1870 elicits bactericidal antibodies. <i>Infection and Immunity</i> , <b>2005</b> , 73, 1151-60	3.7	85
309	NadA diversity and carriage in <i>Neisseria meningitidis</i> . <i>Infection and Immunity</i> , <b>2004</b> , 72, 4217-23	3.7	122
308	Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 828-32	7	48
307	Therapeutic vaccination against <i>Helicobacter pylori</i> in the beagle dog experimental model: safety, immunogenicity, and efficacy. <i>Infection and Immunity</i> , <b>2004</b> , 72, 3252-9	3.7	71

306	Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1177-82	7	23
305	Effect of heparin binding on Helicobacter pylori resistance to serum. <i>Journal of Medical Microbiology</i> , <b>2004</b> , 53, 9-12	3.2	12
304	Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. <i>Infection and Immunity</i> , <b>2004</b> , 72, 4052-60	3.7	54
303	Dual control of Helicobacter pylori heat shock gene transcription by HspR and HrcA. <i>Journal of Bacteriology</i> , <b>2004</b> , 186, 2956-65	3.5	28
302	Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1488-97	7	69
301	Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. <i>Journal of Virology</i> , <b>2004</b> , 78, 10328-35	6.6	94
300	GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. <i>Infection and Immunity</i> , <b>2004</b> , 72, 1914-9	3.7	46
299	Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. <i>Journal of Immunology</i> , <b>2004</b> , 173, 7435-43	5.3	53
298	An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. <i>Nature Medicine</i> , <b>2004</b> , 10, 871-5	50.5	563
297	From Pasteur to genomics: progress and challenges in infectious diseases. <i>Nature Medicine</i> , <b>2004</b> , 10, 1177-85	50.5	87
296	Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. <i>Molecular Microbiology</i> , <b>2004</b> , 52, 1081-90	4.1	145
295	The safety of vaccines. <i>Drug Discovery Today</i> , <b>2004</b> , 9, 846-54	8.8	30
294	Helicobacter pylori infection negatively influences pregnancy outcome in a mouse model. <i>Helicobacter</i> , <b>2004</b> , 9, 152-7	4.9	18
293	Novel approaches to vaccine delivery. <i>Pharmaceutical Research</i> , <b>2004</b> , 21, 1519-30	4.5	102
292	N19 polypeptide as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. <i>Infection and Immunity</i> , <b>2004</b> , 72, 4884-7	3.7	26
291	Long-term solutions for the problem of vaccine shortages. <i>Expert Opinion on Biological Therapy</i> , <b>2004</b> , 4, 989-92	5.4	3
290	Genome-derived vaccines. <i>Expert Review of Vaccines</i> , <b>2004</b> , 3, 59-76	5.2	63
289	Models for bacterial infectious diseases: Helicobacter pylori. <i>Drug Discovery Today: Disease Models</i> , <b>2004</b> , 1, 95-100	1.3	1

- 288 Safety and immunogenicity in animals of subunit influenza vaccine given intranasally with mutants of *Escherichia coli* heat-labile enterotoxin (LT). *International Congress Series*, **2004**, 1263, 640-643
- 287 In silico identification of novel bacterial ADP-ribosyltransferases. *International Journal of Medical Microbiology*, **2004**, 293, 471-8 3.7 26
- 286 The multiple cellular activities of the VacA cytotoxin of *Helicobacter pylori*. *International Journal of Medical Microbiology*, **2004**, 293, 589-97 3.7 30
- 285 Biotechnology and vaccines: application of functional genomics to *Neisseria meningitidis* and other bacterial pathogens. *Journal of Biotechnology*, **2004**, 113, 15-32 3.7 43
- 284 The genome revolution in vaccine research. *Current Issues in Molecular Biology*, **2004**, 6, 17-27 2.9 41
- 283 Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of *Neisseria meningitidis* group B. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9542-7 11.5 164
- 282 Phylogeny of the SARS coronavirus. *Science*, **2003**, 302, 1504-5 33.3 69
- 281 *Helicobacter pylori*: after the genomes, back to biology. *Journal of Experimental Medicine*, **2003**, 197, 807-11 16.6 10
- 280 Reverse vaccinology. *Drug Discovery Today*, **2003**, 8, 459-64 8.8 87
- 279 The neutrophil-activating protein of *Helicobacter pylori* (HP-NAP) activates the MAPK pathway in human neutrophils. *European Journal of Immunology*, **2003**, 33, 840-9 6.1 38
- 278 The quest for a vaccine against *Helicobacter pylori*: how to move from mouse to man?. *Microbes and Infection*, **2003**, 5, 749-56 9.3 42
- 277 An anti-repression Fur operator upstream of the promoter is required for iron-mediated transcriptional autoregulation in *Helicobacter pylori*. *Molecular Microbiology*, **2003**, 50, 1329-38 4.1 36
- 276 NarE: a novel ADP-ribosyltransferase from *Neisseria meningitidis*. *Molecular Microbiology*, **2003**, 50, 1055-67 4.1 43
- 275 *Neisseria meningitidis* App, a new adhesin with autocatalytic serine protease activity. *Molecular Microbiology*, **2003**, 48, 323-34 4.1 88
- 274 SARS--beginning to understand a new virus. *Nature Reviews Microbiology*, **2003**, 1, 209-18 22.2 343
- 273 Mutants of the *Escherichia coli* heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. *Expert Review of Vaccines*, **2003**, 2, 285-93 5.2 96
- 272 The real cost of an affordable vaccine for meningococcus A. *Lancet, The*, **2003**, 362, 250-1; author reply 251 4.0 3
- 271 Two years into reverse vaccinology. *Vaccine*, **2003**, 21, 605-10 4.1 81

270	Vir90, a virulence-activated gene coding for a Bordetella pertussis iron-regulated outer membrane protein. <i>Research in Microbiology</i> , <b>2003</b> , 154, 443-50	4	12
269	Reverse vaccinology and genomics. <i>Science</i> , <b>2003</b> , 302, 602	33.3	68
268	Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. <i>Infection and Immunity</i> , <b>2003</b> , 71, 726-32	3.7	102
267	Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1730-40	7	123
266	Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 197, 789-99	16.6	357
265	The iron-responsive regulator fur is transcriptionally autoregulated and not essential in Neisseria meningitidis. <i>Journal of Bacteriology</i> , <b>2003</b> , 185, 6032-41	3.5	37
264	Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 753-8	7	47
263	Antibody-dependent macrophage-mediated activity against Helicobacter pylori in the absence of complement. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 2721-5	6.1	8
262	c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. <i>Molecular Microbiology</i> , <b>2002</b> , 43, 971-80	4.1	354
261	Autoregulation of Helicobacter pylori Fur revealed by functional analysis of the iron-binding site. <i>Molecular Microbiology</i> , <b>2002</b> , 46, 1107-22	4.1	60
260	GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lytic transglycosylase (MltA). <i>FEBS Journal</i> , <b>2002</b> , 269, 3722-31		34
259	Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. <i>Nature Biotechnology</i> , <b>2002</b> , 20, 914-21	44.5	188
258	Evolution of functional polymorphism in the gene coding for the Helicobacter pylori cytotoxin. <i>FEMS Microbiology Letters</i> , <b>2002</b> , 206, 253-8	2.9	17
257	Growth phase-dependent regulation of target gene promoters for binding of the essential orphan response regulator HP1043 of Helicobacter pylori. <i>Journal of Bacteriology</i> , <b>2002</b> , 184, 4800-10	3.5	48
256	NadA, a novel vaccine candidate of Neisseria meningitidis. <i>Journal of Experimental Medicine</i> , <b>2002</b> , 195, 1445-54	16.6	316
255	The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. <i>Infection and Immunity</i> , <b>2002</b> , 70, 3012-9	3.7	32
254	Bacterial pathogen genomics and vaccines. <i>British Medical Bulletin</i> , <b>2002</b> , 62, 45-58	5.4	14
253	Characterization of the HspR-mediated stress response in Helicobacter pylori. <i>Journal of Bacteriology</i> , <b>2002</b> , 184, 2925-30	3.5	26



252	Characterization and immunogenicity of the CagF protein of the cag pathogenicity island of <i>Helicobacter pylori</i> . <i>Infection and Immunity</i> , <b>2002</b> , 70, 6468-70	3.7	11
251	<i>Helicobacter pylori</i> interactions with host serum and extracellular matrix proteins: potential role in the infectious process. <i>Microbiology and Molecular Biology Reviews</i> , <b>2002</b> , 66, 617-29, table of contents	13.2	40
250	Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. <i>Infection and Immunity</i> , <b>2002</b> , 70, 4785-90	3.7	56
249	Reverse vaccinology: a genome-based approach for vaccine development. <i>Expert Opinion on Biological Therapy</i> , <b>2002</b> , 2, 895-905	5.4	44
248	Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V <i>Streptococcus agalactiae</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 12391-6	11.5	405
247	Medicine. The intangible value of vaccination. <i>Science</i> , <b>2002</b> , 297, 937-9	33.3	123
246	New strategies for the prevention and treatment of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Investigational Drugs</i> , <b>2002</b> , 11, 1127-38	5.9	11
245	Structure of the neutrophil-activating protein from <i>Helicobacter pylori</i> . <i>Journal of Molecular Biology</i> , <b>2002</b> , 323, 125-30	6.5	124
244	In vitro selection of high affinity HspR-binding sites within the genome of <i>Helicobacter pylori</i> . <i>Gene</i> , <b>2002</b> , 283, 63-9	3.8	11
243	The neutrophil-activating protein (HP-NAP) of <i>Helicobacter pylori</i> is a potent stimulant of mast cells. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 671-6	6.1	69
242	The Fur repressor controls transcription of iron-activated and -repressed genes in <i>Helicobacter pylori</i> . <i>Molecular Microbiology</i> , <b>2001</b> , 42, 1297-309	4.1	152
241	Allelic variation in the <i>vacA</i> gene of <i>Helicobacter pylori</i> isolated from Chinese patients. <i>Chinese Journal of Digestive Diseases</i> , <b>2001</b> , 2, 17		
240	Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to <i>Haemophilus influenzae</i> type b oligosaccharide: a model for new conjugate vaccines. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 3816-24	6.1	40
239	Neutrophil-activating protein (HP-NAP) versus ferritin (Pfr): comparison of synthesis in <i>Helicobacter pylori</i> . <i>FEMS Microbiology Letters</i> , <b>2001</b> , 199, 143-9	2.9	34
238	Living dangerously: how <i>Helicobacter pylori</i> survives in the human stomach. <i>Nature Reviews Molecular Cell Biology</i> , <b>2001</b> , 2, 457-66	48.7	391
237	The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells. <i>Journal of Immunology</i> , <b>2001</b> , 166, 1863-70	5.3	30
236	A novel mimetic antigen eliciting protective antibody to <i>Neisseria meningitidis</i> . <i>Journal of Immunology</i> , <b>2001</b> , 167, 6487-96	5.3	50
235	Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant <i>Mycobacterium bovis</i> BCG expressing CRM(197), a mutant diphtheria toxin. <i>Infection and Immunity</i> , <b>2001</b> , 69, 869-74	3.7	32



234	Mu-like Prophage in serogroup B <i>Neisseria meningitidis</i> coding for surface-exposed antigens. <i>Infection and Immunity</i> , <b>2001</b> , 69, 2580-8	3.7	41
233	Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin. <i>Infection and Immunity</i> , <b>2001</b> , 69, 3073-81	3.7	16
232	Iron-dependent transcription of the <i>frpB</i> gene of <i>Helicobacter pylori</i> is controlled by the Fur repressor protein. <i>Journal of Bacteriology</i> , <b>2001</b> , 183, 4932-7	3.5	66
231	Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1494-500	7	20
230	Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , <b>2001</b> , 69, 1605-12	3.7	74
229	Reverse vaccinology, a genome-based approach to vaccine development. <i>Vaccine</i> , <b>2001</b> , 19, 2688-91	4.1	295
228	Problems assaying neutrophil activators. <i>Trends in Microbiology</i> , <b>2001</b> , 9, 314-5	12.4	1
227	An abundance of bacterial ADP-ribosyltransferases [implications for the origin of exotoxins and their human homologues. <i>Trends in Microbiology</i> , <b>2001</b> , 9, 308	12.4	
226	Vacuolation induced by VacA toxin of <i>Helicobacter pylori</i> requires the intracellular accumulation of membrane permeant bases, Cl(-) and water. <i>FEBS Letters</i> , <b>2001</b> , 508, 479-83	3.8	24
225	The design of vaccines against <i>Helicobacter pylori</i> and their development. <i>Annual Review of Immunology</i> , <b>2001</b> , 19, 523-63	34.7	187
224	The <i>Helicobacter pylori</i> VacA toxin is a urea permease that promotes urea diffusion across epithelia. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 108, 929-37	15.9	65
223	Repeat-associated phase variable genes in the complete genome sequence of <i>Neisseria meningitidis</i> strain MC58. <i>Molecular Microbiology</i> , <b>2000</b> , 37, 207-15	4.1	212
222	The VacA toxin of <i>Helicobacter pylori</i> identifies a new intermediate filament-interacting protein. <i>EMBO Journal</i> , <b>2000</b> , 19, 48-56	13	48
221	Recombinant <i>Mycobacterium bovis</i> BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live <i>Bordetella pertussis</i> in mice. <i>Infection and Immunity</i> , <b>2000</b> , 68, 4877-83	3.7	83
220	Cell specificity of <i>Helicobacter pylori</i> cytotoxin is determined by a short region in the polymorphic midregion. <i>Infection and Immunity</i> , <b>2000</b> , 68, 3754-7	3.7	65
219	Modulation of innate and acquired immune responses by <i>Escherichia coli</i> heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. <i>Journal of Immunology</i> , <b>2000</b> , 165, 5750-9	5.3	90
218	Pushing the limits of cellular microbiology: microarrays to study bacteria-host cell intimate contacts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 13461-5	11.5	43
217	The neutrophil-activating protein (HP-NAP) of <i>Helicobacter pylori</i> is a protective antigen and a major virulence factor. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 191, 1467-76	16.6	243

216	Immunohistochemical study of lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with <i>Helicobacter pylori</i> . <i>Infection and Immunity</i> , <b>2000</b> , 68, 4769-72	3.7	27
215	Tyrosine phosphorylation of the <i>Helicobacter pylori</i> CagA antigen after cag-driven host cell translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 1263-8	11.5	497
214	Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 191, 587-92	16.6	148
213	Reverse vaccinology. <i>Current Opinion in Microbiology</i> , <b>2000</b> , 3, 445-50	7.9	478
212	A structural overview of the <i>Helicobacter</i> cytotoxin. <i>International Journal of Medical Microbiology</i> , <b>2000</b> , 290, 375-9	3.7	13
211	LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. <i>International Journal of Medical Microbiology</i> , <b>2000</b> , 290, 455-61	3.7	19
210	Complete genome sequence of <i>Neisseria meningitidis</i> serogroup B strain MC58. <i>Science</i> , <b>2000</b> , 287, 1809-15	3.5	986
209	Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. <i>Science</i> , <b>2000</b> , 287, 1816-20	33.3	1084
208	Synthesis, chemical and rheological characterization of new hyaluronic acid-based hydrogels. <i>Journal of Biomaterials Science, Polymer Edition</i> , <b>2000</b> , 11, 383-99	3.5	48
207	Physicochemical characterisation of the pertussis vaccine. <i>Developments in Biologicals</i> , <b>2000</b> , 103, 175-88		
206	Heat-labile enterotoxin of <i>Escherichia coli</i> and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. <i>Immunology Letters</i> , <b>1999</b> , 67, 209-16	4.1	27
205	The <i>Helicobacter pylori</i> neutrophil-activating protein is an iron-binding protein with dodecameric structure. <i>Molecular Microbiology</i> , <b>1999</b> , 34, 238-46	4.1	143
204	Towards deciphering the <i>Helicobacter pylori</i> cytotoxin. <i>Molecular Microbiology</i> , <b>1999</b> , 34, 197-204	4.1	60
203	The vaccine containing recombinant pertussis toxin induces early and long-lasting protection. <i>Biologicals</i> , <b>1999</b> , 27, 99-102	1.8	13
202	Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of <i>Helicobacter pylori</i> is required for its biological activity. <i>EMBO Journal</i> , <b>1999</b> , 18, 5517-27	13	210
201	Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. <i>Vaccine</i> , <b>1999</b> , 17, 1251-63	4.1	55
200	Inhibition of the vacuolating and anion channel activities of the VacA toxin of <i>Helicobacter pylori</i> . <i>FEBS Letters</i> , <b>1999</b> , 460, 221-5	3.8	61
199	<i>Helicobacter pylori</i> vacuolating toxin forms anion-selective channels in planar lipid bilayers: possible implications for the mechanism of cellular vacuolation. <i>Biophysical Journal</i> , <b>1999</b> , 76, 1401-9	2.9	131

198	3D imaging of the 58 kDa cell binding subunit of the Helicobacter pylori cytotoxin. <i>Journal of Molecular Biology</i> , <b>1999</b> , 290, 459-70	6.5	75
197	Helicobacter pylori virulence and genetic geography. <i>Science</i> , <b>1999</b> , 284, 1328-33	33.3	887
196	Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors. <i>Infection and Immunity</i> , <b>1999</b> , 67, 259-65	3.7	19
195	Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. <i>Infection and Immunity</i> , <b>1999</b> , 67, 5892-7	3.7	52
194	Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. <i>Infection and Immunity</i> , <b>1999</b> , 67, 6270-80	3.7	81
193	A conventional beagle dog model for acute and chronic infection with Helicobacter pylori. <i>Infection and Immunity</i> , <b>1999</b> , 67, 3112-20	3.7	38
192	Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. <i>Infection and Immunity</i> , <b>1999</b> , 67, 4400-6	3.7	58
191	MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. <i>Journal of Immunology</i> , <b>1999</b> , 163, 6502-10	5.3	73
190	Molecular approaches for safer and stronger vaccines. <i>Swiss Medical Weekly</i> , <b>1999</b> , 129, 1744-8	3.1	3
189	Characterisation of a monoclonal antibody and its use to purify the cytotoxin of Helicobacter pylori. <i>FEMS Microbiology Letters</i> , <b>1998</b> , 165, 79-84	2.9	13
188	NMR studies on the structure/function correlations of T-cell-epitope analogs from pertussis toxin. <i>FEBS Journal</i> , <b>1998</b> , 254, 313-7		2
187	Sulphated hyaluronic acids: a chemical and biological characterisation. <i>Polymer International</i> , <b>1998</b> , 46, 225-240	3.3	27
186	Pathogenicity island mediates Helicobacter pylori interaction with the host. <i>Folia Microbiologica</i> , <b>1998</b> , 43, 275-8	2.8	8
185	Action site and cellular effects of cytotoxin VacA produced by Helicobacter pylori. <i>Folia Microbiologica</i> , <b>1998</b> , 43, 279-84	2.8	14
184	Effects of the insertion of a nonapeptide from murine IL-1beta on the immunogenicity of carrier proteins delivered by live attenuated Salmonella. <i>Archives of Microbiology</i> , <b>1998</b> , 169, 113-9	3	3
183	Functional analysis of the Helicobacter pylori principal sigma subunit of RNA polymerase reveals that the spacer region is important for efficient transcription. <i>Molecular Microbiology</i> , <b>1998</b> , 30, 121-34	4.1	35
182	Helicobacter pylori: molecular evolution of a bacterial quasi-species. <i>Current Opinion in Microbiology</i> , <b>1998</b> , 1, 96-102	7.9	60
181	Molecular basis of vaccination. <i>Molecular Aspects of Medicine</i> , <b>1998</b> , 19, 1-70	16.7	13

180	TPA and butyrate increase cell sensitivity to the vacuolating toxin of <i>Helicobacter pylori</i> . <i>FEBS Letters</i> , <b>1998</b> , 436, 218-22	3.8	11
179	The acid activation of <i>Helicobacter pylori</i> toxin VacA: structural and membrane binding studies. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 248, 334-40	3.4	78
178	Cell vacuolization induced by <i>Helicobacter pylori</i> VacA toxin: cell line sensitivity and quantitative estimation. <i>Toxicology Letters</i> , <b>1998</b> , 99, 109-15	4.4	31
177	Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of <i>Escherichia coli</i> heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 187, 1123-32	16.6	244
176	Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. <i>International Immunology</i> , <b>1998</b> , 10, 651-62	4.9	119
175	The m2 form of the <i>Helicobacter pylori</i> cytotoxin has cell type-specific vacuolating activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 10212-7	11.5	160
174	Selective inhibition of li-dependent antigen presentation by <i>Helicobacter pylori</i> toxin VacA. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 187, 135-40	16.6	246
173	7.6 Molecular Genetics of <i>Bordetella Pertussis</i> Virulence. <i>Methods in Microbiology</i> , <b>1998</b> , 27, 395-406	2.8	
172	Levels of expression and immunogenicity of attenuated <i>Salmonella enterica</i> serovar typhimurium strains expressing <i>Escherichia coli</i> mutant heat-labile enterotoxin. <i>Infection and Immunity</i> , <b>1998</b> , 66, 224-31	3.7	45
171	Identification of the <i>Helicobacter pylori</i> VacA toxin domain active in the cell cytosol. <i>Infection and Immunity</i> , <b>1998</b> , 66, 6014-6	3.7	93
170	Deletion of the major proteolytic site of the <i>Helicobacter pylori</i> cytotoxin does not influence toxin activity but favors assembly of the toxin into hexameric structures. <i>Infection and Immunity</i> , <b>1998</b> , 66, 5547-50	3.7	20
169	A recombinant live attenuated strain of <i>Vibrio cholerae</i> induces immunity against tetanus toxin and <i>Bordetella pertussis</i> tracheal colonization factor. <i>Infection and Immunity</i> , <b>1998</b> , 66, 1648-53	3.7	22
168	Binding of the <i>Helicobacter pylori</i> vacuolating cytotoxin to target cells. <i>Infection and Immunity</i> , <b>1998</b> , 66, 3981-4	3.7	56
167	Counterselectable markers: untapped tools for bacterial genetics and pathogenesis. <i>Infection and Immunity</i> , <b>1998</b> , 66, 4011-7	3.7	180
166	Selective increase of the permeability of polarized epithelial cell monolayers by <i>Helicobacter pylori</i> vacuolating toxin. <i>Journal of Clinical Investigation</i> , <b>1998</b> , 102, 813-20	15.9	187
165	Adjuvant effect of non-toxic mutants of <i>E. coli</i> heat-labile enterotoxin following intranasal, oral and intravaginal immunization. <i>Developments in Biological Standardization</i> , <b>1998</b> , 92, 123-6		10
164	Effect of <i>helicobacter pylori</i> vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 25022-8	5.4	100
163	Vacuoles induced by <i>Helicobacter pylori</i> toxin contain both late endosomal and lysosomal markers. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 25339-44	5.4	153

162	Identification and characterization of an operon of <i>Helicobacter pylori</i> that is involved in motility and stress adaptation. <i>Journal of Bacteriology</i> , <b>1997</b> , 179, 4676-83	3.5	85
161	Did the inheritance of a pathogenicity island modify the virulence of <i>Helicobacter pylori</i> ?. <i>Trends in Microbiology</i> , <b>1997</b> , 5, 205-8	12.4	147
160	Meningococcal polysaccharide-protein conjugate vaccines. <i>International Journal of Infectious Diseases</i> , <b>1997</b> , 1, 152-157	10.5	14
159	Rational design of vaccines. <i>Nature Medicine</i> , <b>1997</b> , 3, 374-6	50.5	43
158	The small GTP binding protein rab7 is essential for cellular vacuolation induced by <i>Helicobacter pylori</i> cytotoxin. <i>EMBO Journal</i> , <b>1997</b> , 16, 15-24	13	180
157	Current developments in new vaccines for adolescents. <i>Biologicals</i> , <b>1997</b> , 25, 159-63	1.8	1
156	Efficient production of heat-labile enterotoxin mutant proteins by overexpression of dsbA in a degP-deficient <i>Escherichia coli</i> strain. <i>Archives of Microbiology</i> , <b>1997</b> , 167, 280-3	3	32
155	Pertactin antigens extracted from <i>Bordetella pertussis</i> and <i>Bordetella bronchiseptica</i> differ in the isoelectric point. <i>Archives of Microbiology</i> , <b>1997</b> , 168, 437-40	3	
154	Immunobiology of <i>Helicobacter pylori</i> infection. <i>Current Opinion in Immunology</i> , <b>1997</b> , 9, 498-503	7.8	69
153	A tRNA(2Arg) gene of <i>Corynebacterium diphtheriae</i> is the chromosomal integration site for toxinogenic bacteriophages. <i>Molecular Microbiology</i> , <b>1997</b> , 25, 1179-81	4.1	22
152	Transcriptional analysis of the divergent cagAB genes encoded by the pathogenicity island of <i>Helicobacter pylori</i> . <i>Molecular Microbiology</i> , <b>1997</b> , 26, 361-72	4.1	51
151	<i>Helicobacter pylori</i> toxin VacA induces vacuole formation by acting in the cell cytosol. <i>Molecular Microbiology</i> , <b>1997</b> , 26, 665-74	4.1	116
150	Crystal structure of a non-toxic mutant of heat-labile enterotoxin, which is a potent mucosal adjuvant. <i>Protein Science</i> , <b>1997</b> , 6, 2650-4	6.3	21
149	Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. <i>Infection and Immunity</i> , <b>1997</b> , 65, 331-4	3.7	45
148	Detoxification of the <i>Helicobacter pylori</i> cytotoxin. <i>Infection and Immunity</i> , <b>1997</b> , 65, 4615-9	3.7	21
147	Therapeutic intragastric vaccination against <i>Helicobacter pylori</i> in mice eradicates an otherwise chronic infection and confers protection against reinfection. <i>Infection and Immunity</i> , <b>1997</b> , 65, 4996-5002	3.7	148
146	Preclinical evaluation of group B <i>Neisseria meningitidis</i> and <i>Escherichia coli</i> K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. <i>Infection and Immunity</i> , <b>1997</b> , 65, 1045-52	3.7	33
145	Introduction of unmarked mutations in the <i>Helicobacter pylori</i> vacA gene with a sucrose sensitivity marker. <i>Infection and Immunity</i> , <b>1997</b> , 65, 1949-52	3.7	86

144	Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. <i>Infection and Immunity</i> , <b>1997</b> , 65, 2821-8	3.7	131
143	Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. <i>Journal of Clinical Microbiology</i> , <b>1997</b> , 35, 553-7	9.7	63
142	Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?. <i>Developments in Biological Standardization</i> , <b>1997</b> , 89, 379-89		8
141	Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin. <i>Journal of Cell Biology</i> , <b>1996</b> , 133, 801-7	7.3	160
140	Novel molecular biology approaches to acellular vaccines. <i>Biotechnology Annual Review</i> , <b>1996</b> , 2, 391-408		6
139	Cellular microbiology emerging. <i>Science</i> , <b>1996</b> , 271, 315-6	33.3	137
138	DNA binding of the Bordetella pertussis H1 homolog alters in vitro DNA flexibility. <i>Journal of Bacteriology</i> , <b>1996</b> , 178, 2982-5	3.5	6
137	cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 14648-53	11.5	1559
136	The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. <i>Immunology</i> , <b>1996</b> , 89, 483-7	7.8	67
135	Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. <i>Molecular Microbiology</i> , <b>1996</b> , 21, 667-74	4.1	131
134	Differential binding of BvgA to two classes of virulence genes of Bordetella pertussis directs promoter selectivity by RNA polymerase. <i>Molecular Microbiology</i> , <b>1996</b> , 21, 557-65	4.1	47
133	The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. <i>Journal of Medical Microbiology</i> , <b>1996</b> , 45, 84-9	3.2	39
132	Detection of a vacuolating cytotoxin in stools from children with diarrhea. <i>Clinical Infectious Diseases</i> , <b>1996</b> , 23, 101-6	11.6	13
131	Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. <i>Infection and Immunity</i> , <b>1996</b> , 64, 4172-81	3.7	56
130	Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin. <i>Infection and Immunity</i> , <b>1996</b> , 64, 5434-8	3.7	30
129	Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. <i>Infection and Immunity</i> , <b>1996</b> , 64, 974-9	3.7	175
128	The pertussis toxin liberation genes of Bordetella pertussis are transcriptionally linked to the pertussis toxin operon. <i>Infection and Immunity</i> , <b>1996</b> , 64, 1458-60	3.7	8
127	Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. <i>Infectious Agents and Disease</i> , <b>1996</b> , 5, 21-8		10



126	The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. <i>Developments in Biological Standardization</i> , <b>1996</b> , 87, 125-34		11
125	Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin. <i>Clinical and Experimental Immunology</i> , <b>1995</b> , 99, 473-8	6.2	11
124	Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. <i>Scandinavian Journal of Immunology</i> , <b>1995</b> , 42, 557-64	3.4	34
123	Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins of <i>Escherichia coli</i> and <i>Vibrio cholerae</i> . <i>Molecular Microbiology</i> , <b>1995</b> , 15, 1165-7	4.1	37
122	A novel chromatin-forming histone H1 homologue is encoded by a dispensable and growth-regulated gene in <i>Bordetella pertussis</i> . <i>Molecular Microbiology</i> , <b>1995</b> , 15, 871-81	4.1	13
121	Low pH activates the vacuolating toxin of <i>Helicobacter pylori</i> , which becomes acid and pepsin resistant. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 23937-40	5.4	173
120	Mutants of <i>Escherichia coli</i> heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 1644-8	11.5	260
119	Development of a mouse model of <i>Helicobacter pylori</i> infection that mimics human disease. <i>Science</i> , <b>1995</b> , 267, 1655-8	33.3	520
118	Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular	3.6	16
117	Genetic detoxification of bacterial toxins: a new approach to vaccine development. <i>International Archives of Allergy and Immunology</i> , <b>1995</b> , 108, 327-33	3.7	23
116	Improving membrane filtration processes. <i>Trends in Biotechnology</i> , <b>1995</b> , 13, 129-131	15.1	6
115	Lipid interaction of the 37-kDa and 58-kDa fragments of the <i>Helicobacter pylori</i> cytotoxin. <i>FEBS Journal</i> , <b>1995</b> , 234, 947-52		50
114	IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells. IL-2 release, but not IL-2 receptor expression, is sensitive to pertussis toxin. <i>Journal of Immunology</i> , <b>1995</b> , 155, 181-9	5.3	11
113	Analysis of expression of CagA and VacA virulence factors in 43 strains of <i>Helicobacter pylori</i> reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. <i>Infection and Immunity</i> , <b>1995</b> , 63, 94-8	3.7	442
112	Role of the <i>Helicobacter pylori</i> virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. <i>Infection and Immunity</i> , <b>1995</b> , 63, 4154-60	3.7	164
111	<i>Helicobacter pylori</i> cytotoxin: importance of native conformation for induction of neutralizing antibodies. <i>Infection and Immunity</i> , <b>1995</b> , 63, 4476-80	3.7	81
110	<i>Helicobacter pylori</i> -specific CD4+ T-cell clones from peripheral blood and gastric biopsies. <i>Infection and Immunity</i> , <b>1995</b> , 63, 1102-6	3.7	77
109	A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. <i>Infection and Immunity</i> , <b>1995</b> , 63, 2100-8	3.7	75



108	Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. <i>Infection and Immunity</i> , <b>1995</b> , 63, 2356-60	3.7	67
107	Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. <i>Physiological Chemistry and Physics and Medical NMR</i> , <b>1995</b> , 27, 355-61		4
106	A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180, 2147-53	16.6	102
105	Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. <i>Trends in Biotechnology</i> , <b>1994</b> , 12, 420-6	15.1	71
104	Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins. <i>Molecular Microbiology</i> , <b>1994</b> , 14, 41-50	4.1	109
103	Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. <i>Molecular Microbiology</i> , <b>1994</b> , 14, 51-60	4.1	114
102	Mutations in the linker region of BvgS abolish response to environmental signals for the regulation of the virulence factors in Bordetella pertussis. <i>Gene</i> , <b>1994</b> , 150, 123-7	3.8	27
101	Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. <i>Journal of Pediatrics</i> , <b>1994</b> , 124, 921-6	3.6	32
100	Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 9720-4	11.5	201
99	Pertussis toxin interferes with superantigen-induced deletion of peripheral T cells without affecting T cell activation in vivo. Inhibition of deletion and associated programmed cell death depends on ADP-ribosyltransferase activity. <i>Journal of Immunology</i> , <b>1994</b> , 152, 4291-9	5.3	17
98	Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. <i>Infection and Immunity</i> , <b>1994</b> , 62, 1830-4	3.7	41
97	Pertussis toxin activates platelets through an interaction with platelet glycoprotein Ib. <i>Infection and Immunity</i> , <b>1994</b> , 62, 3108-14	3.7	25
96	Development of the new acellular recombinant pertussis vaccine. <i>Archives De L'Institut Pasteur De Tunis</i> , <b>1994</b> , 71, 557-63		
95	Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. <i>Journal of Pediatrics</i> , <b>1993</b> , 123, 81-4	3.6	25
94	Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous hemagglutinin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1993</b> , 90, 9204-8	11.5	44
93	Inhibition of Helicobacter pylori urease by omeprazole. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1993</b> , 5, 683-686	2.2	39
92	DNA topology affects transcriptional regulation of the pertussis toxin gene of Bordetella pertussis in Escherichia coli and in vitro. <i>Journal of Bacteriology</i> , <b>1993</b> , 175, 4764-71	3.5	23
91	Environmental regulation of virulence factors in Bordetella species. <i>BioEssays</i> , <b>1993</b> , 15, 99-104	4.1	24

90	Bafilomycin A1 inhibits <i>Helicobacter pylori</i> -induced vacuolization of HeLa cells. <i>Molecular Microbiology</i> , <b>1993</b> , 7, 323-7	4.1	117
89	Pertussis toxin export requires accessory genes located downstream from the pertussis toxin operon. <i>Molecular Microbiology</i> , <b>1993</b> , 8, 429-34	4.1	99
88	The Hsp60 protein of <i>Helicobacter pylori</i> : structure and immune response in patients with gastroduodenal diseases. <i>Molecular Microbiology</i> , <b>1993</b> , 9, 645-52	4.1	110
87	Cell vacuolization induced by <i>Helicobacter pylori</i> : inhibition by bafilomycins A1, B1, C1 and D. <i>FEMS Microbiology Letters</i> , <b>1993</b> , 113, 155-9	2.9	23
86	Priming to heat shock proteins in infants vaccinated against pertussis. <i>Journal of Immunology</i> , <b>1993</b> , 150, 2025-32	5.3	35
85	Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 1567-74	5.4	78
84	Growth of <i>Helicobacter pylori</i> in media containing cyclodextrins. <i>Journal of Clinical Microbiology</i> , <b>1993</b> , 31, 160-2	9.7	65
83	Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 2990-4	11.5	17
82	Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children. <i>Journal of Pediatrics</i> , <b>1992</b> , 120, 680-5	3.6	46
81	Functional analysis of the pertussis toxin promoter. <i>Research in Microbiology</i> , <b>1992</b> , 143, 671-81	4	12
80	Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin. <i>Immunobiology</i> , <b>1992</b> , 184, 230-9	3.4	11
79	Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. <i>Vaccine</i> , <b>1992</b> , 10, 691-8	4.1	133
78	Molecular epidemiology of nasopharyngeal corynebacteria in healthy adults from an area where diphtheria vaccination has been extensively practiced. <i>European Journal of Epidemiology</i> , <b>1992</b> , 8, 560-7	12.1	7
77	Thermoregulation and reversible differentiation in <i>Bordetella</i> : a model for pathogenic bacteria. <i>Molecular Microbiology</i> , <b>1992</b> , 6, 2209-11	4.1	19
76	Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and <i>Bacillus Calmette Guérin</i> priming. <i>European Journal of Immunology</i> , <b>1992</b> , 22, 1365-72	6.1	108
75	Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin. <i>Infection and Immunity</i> , <b>1992</b> , 60, 5071-7	3.7	24
74	Cellular pertussis vaccine containing a <i>Bordetella pertussis</i> strain that produces a nontoxic pertussis toxin molecule. <i>Infection and Immunity</i> , <b>1992</b> , 60, 1150-5	3.7	13
73	Generation of human monoclonal antibodies that confer protection against pertussis toxin. <i>Infection and Immunity</i> , <b>1992</b> , 60, 1258-60	3.7	7

72	Towards third-generation whooping cough vaccines. <i>Trends in Biotechnology</i> , <b>1991</b> , 9, 232-8	15.1	12
71	Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding. <i>Molecular Microbiology</i> , <b>1991</b> , 5, 23-31	4.1	63
70	Structural and genetic analysis of the bvg locus in Bordetella species. <i>Molecular Microbiology</i> , <b>1991</b> , 5, 2481-91	4.1	78
69	The bvg-dependent promoters show similar behaviour in different Bordetella species and share sequence homologies. <i>Molecular Microbiology</i> , <b>1991</b> , 5, 2493-8	4.1	20
68	Determination of diphtheria toxin neutralizing antibody titers with a cell protein synthesis inhibition assay. <i>Medical Microbiology and Immunology</i> , <b>1991</b> , 180, 29-35	4	5
67	Differential response of the bvg virulence regulon of Bordetella pertussis to MgSO <sub>4</sub> modulation. <i>Journal of Bacteriology</i> , <b>1991</b> , 173, 7401-4	3.5	32
66	Tyrosine 65 is photolabeled by 8-azidoadenine and 8-azidoadenosine at the NAD binding site of diphtheria toxin. <i>Journal of Biological Chemistry</i> , <b>1991</b> , 266, 2494-8	5.4	23
65	Lymphokine secretion and cytotoxic activity of human CD4 <sup>+</sup> T-cell clones against Bordetella pertussis. <i>Infection and Immunity</i> , <b>1991</b> , 59, 3768-73	3.7	38
64	Properties of the B oligomer of pertussis toxin. <i>Infection and Immunity</i> , <b>1991</b> , 59, 4732-4	3.7	41
63	Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. <i>Infection and Immunity</i> , <b>1991</b> , 59, 625-30	3.7	72
62	Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses. <i>Infection and Immunity</i> , <b>1991</b> , 59, 3313-5	3.7	14
61	Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. <i>EMBO Journal</i> , <b>1991</b> , 10, 3971-5	13	51
60	Further analysis of the sequence of the S1 subunit of pertussis toxin. <i>Infection and Immunity</i> , <b>1991</b> , 59, 1177-9	3.7	1
59	Positive transcriptional feedback at the bvg locus controls expression of virulence factors in Bordetella pertussis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 6753-7	11.5	115
58	Genetic characterization of Bordetella pertussis filamentous haemagglutinin: a protein processed from an unusually large precursor. <i>Molecular Microbiology</i> , <b>1990</b> , 4, 787-800	4.1	102
57	DNA sequence homology between attB-related sites of Corynebacterium diphtheriae, Corynebacterium ulcerans, Corynebacterium glutamicum, and the attP side of $\phi$ -Corynephage. <i>FEMS Microbiology Letters</i> , <b>1990</b> , 66, 299-301	2.9	6
56	Histidine-21 is involved in diphtheria toxin NAD <sup>+</sup> binding. <i>Toxicon</i> , <b>1990</b> , 28, 631-5	2.8	20
55	Haemophilus influenzae infections and whooping cough. <i>Lancet, The</i> , <b>1990</b> , 335, 1324-9	40	39

54	The subunit S1 is important for pertussis toxin secretion. <i>Journal of Biological Chemistry</i> , <b>1990</b> , 265, 17759-63	3.8	38
53	Identification of a 35-kilodalton Mycobacterium tuberculosis protein containing B- and T-cell epitopes. <i>Infection and Immunity</i> , <b>1990</b> , 58, 245-51	3.7	9
52	Biochemical and biological activities of recombinant S1 subunit of pertussis toxin. <i>Infection and Immunity</i> , <b>1990</b> , 58, 999-1003	3.7	8
51	Pertussis toxin promoter sequences involved in modulation. <i>Journal of Bacteriology</i> , <b>1989</b> , 171, 4026-30	3.5	48
50	Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. <i>Journal of Experimental Medicine</i> , <b>1989</b> , 169, 1519-32	16.6	56
49	Selective immunotoxins prepared with mutant diphtheria toxins coupled to monoclonal antibodies. <i>Methods in Enzymology</i> , <b>1989</b> , 178, 404-22	1.7	3
48	Genetics of pertussis toxin. <i>Molecular Microbiology</i> , <b>1989</b> , 3, 119-24	4.1	31
47	Families of bacterial signal-transducing proteins. <i>Molecular Microbiology</i> , <b>1989</b> , 3, 1661-7	4.1	165
46	Phase variants of Bordetella bronchiseptica arise by spontaneous deletions in the vir locus. <i>Molecular Microbiology</i> , <b>1989</b> , 3, 1719-28	4.1	75
45	Studies of the antigenic structure of two cross-reacting proteins, pertussis and cholera toxins, using synthetic peptides. <i>Molecular Immunology</i> , <b>1989</b> , 26, 95-100	4.3	11
44	Mutants of pertussis toxin suitable for vaccine development. <i>Science</i> , <b>1989</b> , 246, 497-500	33.3	281
43	Sequences required for expression of Bordetella pertussis virulence factors share homology with prokaryotic signal transduction proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 6671-5	11.5	257
42	Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 2637-41	11.5	286
41	Histidine 21 is at the NAD <sup>+</sup> binding site of diphtheria toxin. <i>Journal of Biological Chemistry</i> , <b>1989</b> , 264, 12385-8	5.4	43
40	Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD. <i>Infection and Immunity</i> , <b>1989</b> , 57, 3549-54	3.7	53
39	Cloning of a novel pilin-like gene from Bordetella pertussis: homology to the fim2 gene. <i>Molecular Microbiology</i> , <b>1988</b> , 2, 539-43	4.1	32
38	Monoclonal antibodies against pertussis toxin subunits. <i>FEMS Microbiology Letters</i> , <b>1988</b> , 51, 7-11	2.9	14
37	Molecular epidemiology of the 1984-1986 outbreak of diphtheria in Sweden. <i>New England Journal of Medicine</i> , <b>1988</b> , 318, 12-4	59.2	91

36	Cytoskeletal alterations as a parameter for assessment of toxicity. <i>Xenobiotica</i> , <b>1988</b> , 18, 715-24	2	12
35	Dissecting human T cell responses against Bordetella species. <i>Journal of Experimental Medicine</i> , <b>1988</b> , 168, 1351-62	16.6	65
34	Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 7521-5	11.5	92
33	Positive regulation of pertussis toxin expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 3913-7	11.5	90
32	A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity. <i>Journal of Immunology</i> , <b>1988</b> , 140, 2466-71	5.3	11
31	On the membrane translocation of diphtheria toxin: at low pH the toxin induces ion channels on cells. <i>EMBO Journal</i> , <b>1988</b> , 7, 3353-9	13	19
30	The nucleotide sequence of the gene coding for diphtheria toxoid CRM176. <i>Nucleic Acids Research</i> , <b>1987</b> , 15, 5897	20.1	5
29	Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. <i>Journal of Bacteriology</i> , <b>1987</b> , 169, 2847-53	3.5	185
28	High-level expression of a proteolytically sensitive diphtheria toxin fragment in Escherichia coli. <i>Journal of Bacteriology</i> , <b>1987</b> , 169, 5140-51	3.5	45
27	Diphtheria toxin and its mutant crm 197 differ in their interaction with lipids. <i>FEBS Letters</i> , <b>1987</b> , 215, 73-8	3.8	27
26	Conformational changes in diphtheria toxoids. Analysis with monoclonal antibodies. <i>FEBS Letters</i> , <b>1987</b> , 218, 271-6	3.8	22
25	DNA element of Corynebacterium diphtheriae with properties of an insertion sequence and usefulness for epidemiological studies. <i>Journal of Bacteriology</i> , <b>1987</b> , 169, 308-12	3.5	29
24	Promoter of the pertussis toxin operon and production of pertussis toxin. <i>Journal of Bacteriology</i> , <b>1987</b> , 169, 2843-6	3.5	54
23	Evolutionary relationships in the genus Bordetella. <i>Molecular Microbiology</i> , <b>1987</b> , 1, 301-8	4.1	75
22	Lipid interaction of diphtheria toxin and mutants with altered fragment B. 1. Liposome aggregation and fusion. <i>FEBS Journal</i> , <b>1987</b> , 169, 629-35		36
21	Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication. <i>FEBS Journal</i> , <b>1987</b> , 169, 637-44		59
20	Expression and immunological properties of the five subunits of pertussis toxin. <i>Infection and Immunity</i> , <b>1987</b> , 55, 963-7	3.7	93
19	Expression of the S-1 catalytic subunit of pertussis toxin in Escherichia coli. <i>Infection and Immunity</i> , <b>1987</b> , 55, 1321-3	3.7	23

18	Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1986</b> , 83, 4631-5	11.5	287
17	Hydrophobic photolabelling of pertussis toxin subunits interacting with lipids. <i>FEBS Letters</i> , <b>1986</b> , 194, 301-4	3.8	17
16	Detection of homology to the beta bacteriophage integration site in a wide variety of <i>Corynebacterium</i> spp. <i>Journal of Bacteriology</i> , <b>1986</b> , 168, 103-8	3.5	14
15	Production of Large Quantities of Diphtheria Toxoid CRM45. <i>Bio/technology</i> , <b>1985</b> , 3, 161-163		3
14	Detection and physical map of a omega tox+-related defective prophage in <i>Corynebacterium diphtheriae</i> Belfanti 1030(-)tox-. <i>Journal of Virology</i> , <b>1985</b> , 54, 194-8	6.6	5
13	The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. <i>Nucleic Acids Research</i> , <b>1984</b> , 12, 4063-9	20.1	218
12	IgA-dependent cell-mediated activity against enteropathogenic bacteria: distribution, specificity, and characterization of the effector cells. <i>Journal of Immunology</i> , <b>1984</b> , 133, 988-92	5.3	51
11	Physical map of the chromosomal region of <i>Corynebacterium diphtheriae</i> containing corynephage attachment sites attB1 and attB2. <i>Journal of Bacteriology</i> , <b>1984</b> , 158, 325-30	3.5	22
10	Rapid purification of diphtheria toxin by phenyl sepharose and DEAE-cellulose chromatography. <i>Journal of Chromatography A</i> , <b>1983</b> , 268, 543-548	4.5	24
9	The complete nucleotide sequence of the gene coding for diphtheria toxin in the corynephage omega (tox+) genome. <i>Nucleic Acids Research</i> , <b>1983</b> , 11, 6589-95	20.1	106
8	Isolation and characterization of <i>Corynebacterium diphtheriae</i> nontandem double lysogens hyperproducing CRM197. <i>Applied and Environmental Microbiology</i> , <b>1983</b> , 46, 560-4	4.8	39
7	Integration of corynebacteriophages beta tox+, omega tox+, and gamma tox- into two attachment sites on the <i>Corynebacterium diphtheriae</i> chromosome. <i>Journal of Bacteriology</i> , <b>1983</b> , 153, 1202-10	3.5	43
6	Restriction endonuclease map of corynebacteriophage omega ctox+ isolated from the Park-Williams no. 8 strain of <i>Corynebacterium diphtheriae</i> . <i>Journal of Virology</i> , <b>1983</b> , 45, 524-30	6.6	30
5	Restriction endonuclease map of the nontoxigenic corynephage gamma c and its relationship to the toxigenic corynephage beta c. <i>Journal of Virology</i> , <b>1982</b> , 42, 510-18	6.6	32
4	Competitive enzyme immunoassay for human chorionic somatomammotropin using the avidin-biotin system. <i>Analytical Biochemistry</i> , <b>1981</b> , 118, 168-72	3.1	17
3	Restriction map of corynebacteriophages beta c and beta vir and physical localization of the diphtheria tox operon. <i>Journal of Bacteriology</i> , <b>1981</b> , 148, 124-30	3.5	34
2	Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients		16
1	Extremely potent human monoclonal antibodies from convalescent Covid-19 patients		6

